Wolkotte Chantalle, Hassell Daxenos R, Moret Karin, Gerlag Paul G, van den Wall Bake A Warmold, van der Sande Frank M, Kooman Jeroen P
Department of Internal Medicine, St. Joseph Hospital Veldhoven, Maastricht, The Netherlands.
Nephron. 2002;92(3):605-9. doi: 10.1159/000064088.
In earlier studies, a reduction in intradialytic procedures was observed in patients with severe intradialytic hypotension symptomatology by the use of blood volume controlled biofeedback systems. However, few data are present on the use of biofeedback-controlled treatments in patients experiencing minor intradialytic symptoms. In the present study, 157 standard and 158 biofeedback-controlled treatments were compared during a 2-month period in 16 hemodialysis patients. Both the percentage of hypotensive episodes (6.3 +/- 11.3 vs. 15.8 +/- 18.3%; p < 0.05) as well as other intradialytic symptoms (cramps, nausea, headache, abdominal pain) (11.0 +/- 12.8 vs. 18.1 +/- 16.9%; p < 0.05) were significantly less during biofeedback-controlled treatments compared to standard dialysis treatments, despite a similar decline in relative blood volume (8.8 +/- 3.5 vs. 8.3 +/- 3.1%; p = n.s.). Interdialytic weight gain and intradialytic rise in plasma sodium levels were comparable. Concluding, in this short-term preliminary study, blood volume controlled biofeedback improved dialysis tolerance also in patients with minor intradialytic symptomatology.
在早期研究中,通过使用血容量控制生物反馈系统,观察到有严重透析中低血压症状的患者透析期间的操作次数减少。然而,关于生物反馈控制治疗在有轻微透析中症状的患者中的应用,目前的数据很少。在本研究中,对16例血液透析患者在2个月期间的157次标准治疗和158次生物反馈控制治疗进行了比较。与标准透析治疗相比,生物反馈控制治疗期间低血压发作的百分比(6.3±11.3对15.8±18.3%;p<0.05)以及其他透析中症状(痉挛、恶心、头痛、腹痛)(11.0±12.8对18.1±16.9%;p<0.05)均显著减少,尽管相对血容量下降相似(8.8±3.5对8.3±3.1%;p=无显著差异)。透析间期体重增加和透析中血浆钠水平升高相当。总之,在这项短期初步研究中,血容量控制生物反馈也改善了有轻微透析中症状患者的透析耐受性。